March 31 (Reuters) - Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its ...

Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and ...

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and ...

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will ...

Biogen (NASDAQ:BIIB) executives outlined their rationale and financial expectations for a proposed acquisition of Apellis ...

Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking ...

Biogen is opening its wallet in a big way, agreeing to buy Apellis Pharmaceuticals in an all-cash deal that values the ...

Preview this article 1 min Biogen is buying a Boston-area biotech that already has two approved drugs to drive short-term and ...

Biogen (BIIB) just cleared two important milestones, with FDA approval of a new High Dose Regimen for SPINRAZA in spinal muscular atrophy and positive Phase 2 data for litifilimab in cutaneous lupus ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

March 31 (Reuters) - Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its ...

Biogen is buying Apellis Pharmaceuticals for $5.6 billion upfront as it looks to expand its immunology business.